Overview

Also Known As:mAKAP^fl

These mAKAP6^fl mutant mice possess loxP sites flanking exon 9 of the A kinase (PRKA) anchor protein 6 (Akap6) gene, a scaffold protein located in the nuclear envelope of striated myocytes. This strain may be useful for studying cardiac hypertrophy and heart failure.

Donating Investigator

Michael Kapiloff, University of Miami

Genetic overview

Genetic Background	Generation

Akap6^tm1.1Mskf

Allele Type	Gene Symbol	Gene Name
Targeted (Conditional ready (e.g. floxed), No functional change)	Akap6	A kinase (PRKA) anchor protein 6

View Genetics

Research Applications

Research Tools

View All Research Applications

Details

Detailed Description

These mAKAP6^fl mutant mice possess loxP sites flanking exon 9 of the A kinase (PRKA) anchor protein 6 (Akap6) gene. Akap6 is a scaffold protein located in the nuclear envelope of striated myocytes; it functions as nodal organizer of hypertrophic signaling. Mice that are homozygous for this allele are viable, fertile, and normal in size. When bred to mice that express tissue-specific Cre recombinase, resulting offspring will have exon 9 deleted in the cre-expressing tissues. This strain may be useful for studying cardiac hypertrophy and heart failure.

When bred to mice carrying Tg(Myh6-cre/Esr1*)1Jmk, tamoxifen-induced Cre-mediated recombination and stress by transverse aortic constriction results in a cardiac protective effect when compared to controls subjected to the same regime.

Development

The targeting vector contains a FRT-flanked neomycin cassette followed by a loxP site upstream exon 9 and loxP downstream of exon 9. The targeting vector was introduced to unspecified C57BL/6-derived embryonic stem (ES) cells. The neomycin resistance cassette was subsequently excised by crossing to
B6;SJL-Tg(ACTFLPe)9205Dym/J mice, leaving exon 9 flanked by loxP sites. Progeny were crossed to remove the FLPe-expressing transgene. This strain was backcrossed to C57BL/6 for an unknown number generations by the donating investigator. Upon arrival at The Jackson Laboratory, mice were bred to C57BL/6J for at least 1 generation to establish the colony.

Control Suggestions

Wild-type littermate

Additional Information

Considerations for Choosing Controls

Selected References

Kritzer MD; Li J; Passariello CL; Gayanilo M; Thakur H; Dayan J; Dodge-Kafka K; Kapiloff MS. 2014. The scaffold protein muscle A-kinase anchoring protein beta orchestrates cardiac myocyte hypertrophic signaling required for the development of heart failure. Circ Heart Fail 7(4):663-72PubMed: 24812305 MGI: J:214288

View All References

Genetics

Akap6^tm1.1Mskf

Allele Symbol: Akap6^tm1.1Mskf

Allele Name	targeted mutation 1.1, Michael S Kapiloff
Allele Type	Targeted (Conditional ready (e.g. floxed), No functional change)
Allele Synonym(s)	mAKAP^fl
Gene Symbol and Name	Akap6, A kinase (PRKA) anchor protein 6
Gene Synonym(s)
Strain of Origin	C57BL/6
Chromosome	12
Molecular Note	The targeting vector contains a FRT-flanked neomycin cassette followed by a loxP site upstream exon 9 and loxP downstream of exon 9. Flpe mediated recombination removed the FRT-flanked neo cassette leaving exon 9 floxed.

Disease/Phenotype

Disease Terms

Research Areas By Phenotype

This mouse can be used to support research in many areas including:

Research Tools
- Cardiovascular Research
  - Cre-lox System
- Cre-lox System
  - loxP-flanked Sequences

Mammalian Phenotype Terms by Genotype

The following phenotype information is associated with a similar, but not exact match to this JAX^® Mice strain

Genotype: Akap6^tm1.1Mskf/Akap6^tm1.1Mskf A1cf^{Tg(Myh6-cre/Esr1)1Jmk}/A1cf⁺
involves: C57BL/6 FVB/N * SJL

cardiovascular system phenotype

abnormal heart ventricles weight
- following 2 weeks of cardiac stress by transverse aortic constriction (TAC) or isoproterenol infusion, mice administered tamoxifen exhibit increased biventricular weight, but to a much lessor extent than controls subjected to the same regime
- following a 5 week swimming regime, mice administered tamoxifen exhibit an increase in biventricular weight gain, but to a lessor extent than controls subjected to the same regime (13% vs 5%)

cardiac interstitial fibrosis
- following a long term LT-TAC, mice administered tamoxifen exhibit increased collagen deposistion, but 78% less collagen deposition as compared controls subjected to the same regime

decreased heart rate
- following a 5 week swimming regime, mice administered tamoxifen exhibit lower heart rate than controls subjected to the same regime

enlarged myocardial fiber
- following 2 weeks of TAC or isoproterenol infusion, left venticle (LV) myocytes from mice administered tamoxifen exhibit an increase in cross section area, but to a much lessor extent than controls subjected to the same regime

heart left ventricle hypertrophy
- following a long term (LT) TAC, mice administered tamoxifen die as a result of congenital heart failure, but exhibit greater survival than controls subjected to the same regime (6% vs 29%) and do not exhibit pulmonary edema

increased cardiomyocyte apoptosis
- following a long term LT-TAC, mice administered tamoxifen exhibit increased apoptosis, but 75% less myocardial apoptosis as compared controls subjected to the same regime

increased heart left atrium weight
- to the same regime
- following cardiac stress by long term transverse aortic constriction (LT-TAC), mice administered tamoxifen exhibit increased left atrial weight (35%) as compared controls undergoing a sham procedure, but less than the increase (50%) in controls subjected to the same regime

increased left ventricle weight
- following a LT-TAC, mice administered tamoxifen die as a result of congenital heart failure, but exhibit greater survival than controls subjected to the same regime (6% vs 29%) and do not exhibit pulmonary edema

thick ventricular wall
- following 2 weeks of TAC or isoproterenol infusion, mice administered tamoxifen exhibit increased left ventricular (LV) wall thickness, but to a much lessor extent than controls subjected to the same regime

cellular phenotype

increased cardiomyocyte apoptosis
- following a long term LT-TAC, mice administered tamoxifen exhibit increased apoptosis, but 75% less myocardial apoptosis as compared controls subjected to the same regime

growth/size/body region phenotype

heart left ventricle hypertrophy
- following a long term (LT) TAC, mice administered tamoxifen die as a result of congenital heart failure, but exhibit greater survival than controls subjected to the same regime (6% vs 29%) and do not exhibit pulmonary edema

increased heart left atrium weight
- to the same regime
- following cardiac stress by long term transverse aortic constriction (LT-TAC), mice administered tamoxifen exhibit increased left atrial weight (35%) as compared controls undergoing a sham procedure, but less than the increase (50%) in controls subjected to the same regime

increased left ventricle weight
- following a LT-TAC, mice administered tamoxifen die as a result of congenital heart failure, but exhibit greater survival than controls subjected to the same regime (6% vs 29%) and do not exhibit pulmonary edema

muscle phenotype

enlarged myocardial fiber
- following 2 weeks of TAC or isoproterenol infusion, left venticle (LV) myocytes from mice administered tamoxifen exhibit an increase in cross section area, but to a much lessor extent than controls subjected to the same regime

heart left ventricle hypertrophy
- following a long term (LT) TAC, mice administered tamoxifen die as a result of congenital heart failure, but exhibit greater survival than controls subjected to the same regime (6% vs 29%) and do not exhibit pulmonary edema

increased cardiomyocyte apoptosis
- following a long term LT-TAC, mice administered tamoxifen exhibit increased apoptosis, but 75% less myocardial apoptosis as compared controls subjected to the same regime

References

Kritzer MD; Li J; Passariello CL; Gayanilo M; Thakur H; Dayan J; Dodge-Kafka K; Kapiloff MS. 2014. The scaffold protein muscle A-kinase anchoring protein beta orchestrates cardiac myocyte hypertrophic signaling required for the development of heart failure. Circ Heart Fail 7(4):663-72PubMed: 24812305 MGI: J:214288

Additional - Akap6^tm1.1Mskf related

Technical Support

CONTACT TECHNICAL SUPPORT

Genotyping Protocols
- Probe:Generic Cre Probe
- Probe:Generic FLP
- Standard PCR:Akap6
- Standard PCR:Generic Neo
- Probe:Generic Neo
- Genotyping resources and troubleshooting
Breeding Considerations

While maintaining a live colony, these mice are bred as homozygotes.
- Additional Breeding and Husbandry Support
Mating System
- Heterozygote x Heterozygote
Citation
When using the mAKAP^fl mouse strain in a publication, please cite the originating article(s) and include MMRRC stock #37540 in your Materials and Methods section.

Animal Health Reports

Facility Barrier Level Descriptions

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.

Terms Of Use

General Terms and Conditions

See MMRRC for Additional Conditions of Distribution

Questions about Terms of Use

Licensing Information

Phone: 207-288-6470

Email: TechTran@jax.org

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCT(S)" means biological materials supplied by JACKSON, and their derivatives. "SERVICES" means projects conducted by JACKSON for other parties that may include but are not limited to the use of MICE or PRODUCTS. "RECIPIENT" means each recipient of MICE, PRODUCTS, or SERVICES provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE, PRODUCTS or SERVICES from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON’s prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED "AS IS". JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

Credit for PRODUCTS or SERVICES

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of, PRODUCTS or SERVICES, JACKSON will, at its option, provide credit or replacement for the PRODUCT received or the SERVICES provided; JACKSON makes no other representations and this shall be the exclusive remedy of the purchaser. Please note specific policy for live mice.

Animal Care and Use for SERVICES

Consistent with the requirement for a written understanding regarding animal care and use, the JACKSON Animal Care and Use Committee will review the animal care and use protocol(s) associated with any SERVICES to be performed at JACKSON, and JACKSON shall have ultimate responsibility and authority for the care of animals while on site or in JACKSON custody.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS, or SERVICES, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS, or SERVICES from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE, PRODUCTS or SERVICES are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or SERVICES. In addition, special terms and conditions of sale of certain MICE, PRODUCTS, or SERVICES may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and SERVICES by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or SERVICES shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or SERVICES by JACKSON.

Also Known As:mAKAPfl

Donating Investigator

Genetic overview

Research Applications

Detailed Description

Development

Control Suggestions

Additional Information

Selected References

Akap6tm1.1Mskf

Allele Symbol: Akap6tm1.1Mskf

Disease Terms

Research Areas By Phenotype

This mouse can be used to support research in many areas including:

Mammalian Phenotype Terms by Genotype

Genotype: Akap6tm1.1Mskf/Akap6tm1.1Mskf A1cfTg(Myh6-cre/Esr1*)1Jmk/A1cf+involves: C57BL/6 * FVB/N * SJL

cardiovascular system phenotype

cellular phenotype

growth/size/body region phenotype

muscle phenotype

References

Additional - Akap6tm1.1Mskf related

Genotyping Protocols

Breeding Considerations

Mating System

Citation

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200

The Jackson Laboratory's Genotype Promise

Terms Of Use

Licensing Information

JAX® Mice, Products & Services Conditions of Use

No Warranty

Credit for PRODUCTS or SERVICES

Animal Care and Use for SERVICES

No Liability

Also Known As:mAKAP^fl

Akap6^tm1.1Mskf

Allele Symbol: Akap6^tm1.1Mskf

Genotype: Akap6^tm1.1Mskf/Akap6^tm1.1Mskf A1cf^{Tg(Myh6-cre/Esr1)1Jmk}/A1cf⁺
involves: C57BL/6 FVB/N * SJL

Additional - Akap6^tm1.1Mskf related